Skip Navigation

This Article
Right arrow Full Text (PDF )
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (34)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Scheele, F.
Right arrow Articles by Schoemaker, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Scheele, F.
Right arrow Articles by Schoemaker, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Reproduction, Vol. 8, No. 5, pp. 699-704, 1993
© 1993 European Society of Human Reproduction and Embryology

other

The effects of a gonadotrophin-releasing hormone agonist on treatment with low dose follicle stimulating hormone in polycystic ovary syndrome

Fedde Scheele1, Peter G.A. Hompes, Maartje van der Meer, Erik Schoute and Joop Schoemaker

Division of Reproductive Endocrinology and Fertility, Department of Obstetrics and Gynaecology, Free University Hospital PO Box 7057, 1007 MB Amsterdam, The Netherlands

Correspondence: 1To whom correspondence should be addressed

The objective of this study was to investigate whether the incidence of monofollicular growth during stimulation with low dose follicle stimulating hormone (FSH) changes when adjuvant gonadotrophin-releasing hormone agonist (GnRHa) pre-treatment is administered in polycystic ovary syndrome (PCOS). One group of patients (group 1) suffering from clomiphene resistant PCOS was stimulated with low dose FSH. The results were compared with those from another group of similar patients (group 2) subsequently stimulated with low dose FSH combined with GnRHa. In group 1 15 patients had 39 stimulation cycles performed; in group 2 13 patients had 33 stimulation cycles performed. In group 1 44% of cycles were monofollicular, whilst the corresponding figure in group 2 was 14% (P = 0.04). Evidence was found for postponed atresia in group 2. In both groups 1 and 2 interindividual and intra-individual variability of the FSH dose inducing follicular growth were observed. We concluded that during the use of GnRHa, stimulation with low dose FSH less frequently resulted in monofollicular growth, possibly due to postponed atresia. Furthermore, the use of GnRHa does not abolish the inter- and intra-individual variability of the FSH dose inducing ongoing follicular growth.

Key words: gonadotrophin-releasing hormone analogue/low dose follicle stimulating hormone/ovulation induction/polycystic ovary/threshold dose


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Hum ReprodHome page
The Thessaloniki ESHRE/ASRM-Sponsored PCOS Consens
Consensus on infertility treatment related to polycystic ovary syndrome
Hum. Reprod., March 1, 2008; 23(3): 462 - 477.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
I. E. Messinis
Ovulation induction: a mini review
Hum. Reprod., October 1, 2005; 20(10): 2688 - 2697.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. van der Meer, P. G. A. Hompes, J. A. M. de Boer, R. Schats, and J. Schoemaker
Cohort Size Rather Than Follicle-Stimulating Hormone Threshold Level Determines Ovarian Sensitivity in Polycystic Ovary Syndrome
J. Clin. Endocrinol. Metab., February 1, 1998; 83(2): 423 - 426.
[Abstract] [Full Text]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.